1	Actionable absolute risk prediction of atherosclerotic
2	cardiovascular disease: a behavior-management approach
3	based on data from 464,547 UK Biobank participants
4	
5	Ajay Kesar ^{1*} , Adel Baluch ¹ , Omer Barber ¹ , Henry Hoffmann ¹ , Milan Jovanovic ¹ , Daniel Renz ¹ ,
6	Bernard Leon Stopak ¹ , Paul Wicks ¹ , Stephen Gilbert ^{1,2}
7	
8	¹ Ada Health GmbH, Berlin, Germany
9	² EKFZ for Digital Health, University Hospital Carl Gustav Carus Dresden, Technische
10	Universität Dresden, Dresden, Germany
11	
12	* Corresponding author
13	E-mail: <u>science@ada.com</u>
14	
15	
16	
17	
18	
19	
20	
21	
22	
23	

24 Abstract

25 Cardiovascular diseases (CVDs) are the primary cause of all global death. Timely and 26 accurate identification of people at risk of developing an atherosclerotic CVD and its sequelae. 27 via risk prediction model, is a central pillar of preventive cardiology. However, currently available 28 models only consider a limited set of risk factors and outcomes, do not focus on providing 29 actionable advice to individuals based on their holistic medical state and lifestyle, are often not 30 interpretable, were built with small cohort sizes or are based on lifestyle data from the 1960s, 31 e.g. the Framingham model. The risk of developing atherosclerotic CVDs is heavily lifestyle 32 dependent, potentially making a high percentage of occurrences preventable. Providing 33 actionable and accurate risk prediction tools to the public could assist in atherosclerotic CVD 34 prevention. We developed a benchmarking pipeline to find the best set of data preprocessing 35 and algorithms to predict absolute 10-year atherosclerotic CVD risk. Based on the data of 36 464,547 UK Biobank participants without atherosclerotic CVD at baseline, we used a 37 comprehensive set of 203 consolidated risk factors associated with atherosclerosis and its 38 sequelae (e.g. heart failure). 39 Our two best performing absolute atherosclerotic risk prediction models provided higher 40 performance than Framingham and QRisk3. Using a subset of 25 risk factors identified with 41 feature selection, our reduced model achieves similar performance while being less complex. 42 Further, it is interpretable, actionable and highly generalizable. The model could be incorporated 43 into clinical practice and could allow continuous personalized predictions with automated 44 intervention suggestions.

- 45
- 46
- 47
- 48

49 Introduction

50 Cardiovascular diseases (CVDs) are the number one cause of all global death (1,2). In 2016, 51 17.9 million people died of CVDs alone, accounting for 31% of all global deaths (1). The direct 52 costs of CVDs in the US for 2010 were \$272.5 billion whereas indirect costs were \$171.7 billion 53 and are expected to increase to \$818.1 and \$275.8 billion in 2030 respectively (3,4). 54 Atherosclerosis alone is responsible for 1.3% of all hospital stavs with costs of \$9 billion per 55 year, while all atherosclerosis-related diseases amount to \$43.5 billion of total hospital costs 56 annually (5). Individually, patients with CVD incur more than twice the medical costs of age- and 57 sex-matched patients without CVD, largely because of the increased likelihood of subsequent 58 hospitalizations. The greatest differences in total CVD costs usually occur when comparing 59 patients with and without a secondary CVD hospitalization (6). 60 All current guidelines on the prevention of CVD in clinical practice recommend the assessment 61 of total CVD risk since atherosclerosis is usually the product of a number of risk factors (7.8) 62 and in recent years these guidelines have evolved to focus on the absolute risk of disease as 63 opposed to relative risk (7–10). Clinician tools for CVD risk estimation must enable rapid and 64 accurate estimation of an individual patient's absolute CVD risk (7), or for opportunistic 65 screening of high-risk patients from relevant populations (11). Screening is the identification of 66 unrecognized disease or risk of disease in individuals without symptoms. In addition to 67 opportunistic screening, which is carried out without a predefined strategy (e.g. when the 68 individual is consulting a general practitioner (GP) for some other reason), tools can be used for 69 systematic screening, which is centrally organised strategic screening in the general population 70 or in targeted subpopulations, such as subjects with a family history of premature CVD or 71 familial hyperlipidaemia (7). There is ongoing debate on the role of systematic centralised 72 population based screening in CVD (10,12), one reason for this being the tendency for 73 increased use of burdensome diagnostic testing following the use of risk based screening

tools(10)(13). A relatively new area of screening is self-screening, carried out by proactive
individuals, using smartphone or smartwatch app based screening tools, which may use built in
app-linked sensors, or screening chat-bots (14–16). There is public demand for reliable,
actionable, explainable and usable health information tools (17), including for disease
screening.

79

80 The risk to build up atherosclerotic plaque varies and is determined by multiple factors such as

81 genetics, environment and lifestyle (11,18–21). With genetics being unmodifiable and the

82 environment being difficult to change, the risk of developing atherosclerotic plaque can be

reduced based on an individual's lifestyle which is modifiable (19,20).

84 Thus, atherosclerotic CVD is actionable and preventable by addressing behavioral risk factors,

such as smoking, physical activity and nutrition (1,11,19,20).

86

87 Most diseases, including atherosclerotic CVDs, have a complex pathophysiology that involves 88 multiple interacting molecular systems, making it insufficient to look only at an isolated biological 89 pathway or a subset of markers to predict disease risk (22). A precision medicine based 90 approach is required, where multiple biological layers are considered (i.e., 'multi-omics'), 91 alongside clinical and lifestyle data (22). Such an approach has the potential to capture all 92 important interactions or correlations detected between molecules in different biological layers, 93 providing a holistic understanding of an individual's current health status and enabling the 94 quantification of an individual's absolute risk of atherosclerotic CVDs (23,24). 95 96 Previous studies in this area use an outdated or very limited set of risk factors and outcomes for 97 their analysis (7,25). In recent years, the knowledge of behavioral risk factors and of the 98 pathophysiology of atherosclerotic CVDs have advanced tremendously (11,25). Current

99 absolute risk prediction models have limited predictive capability as they have not been trained

100 on all possible atherosclerotic CVD outcomes (26-28), or they include outcomes which are unmodifiable such as those related to pregnancy, accidents, or congenital factors (28). 101 102 Both SCORE (Systematic COronary Risk Evaluation) and SCORE2 (29,30), are models for 103 predicting relative CVD risk, whereas we focus on predicting absolute CVD risk, which is why 104 we chose to omit those models from our analysis. Another related investigation, which also used 105 the UK Biobank (UKB) dataset, developed multiple Cox Proportional Hazard models for 10-year 106 CVD risk prediction, with a reduced version requiring 47 risk factors and another version 107 disregarding all cholesterol risk factors as well as systolic blood pressure, in order to provide a 108 simple approach for risk prediction in remote settings with limited testing resources (31). 109 However, survival models such as the proportional hazard model, are not designed to provide 110 absolute risk estimates for individual patients.

111

Machine learning (ML) based approaches have many advantages, such as superior
performance, being able to identify complex non-linear patterns, the ability to encode diverse
and high dimensional data types, being more stable to outliers, allowing continuous model
updates, versatility for different domains and scalability (32–35).

116 However, classic disadvantages of ML based approaches are their lack of interpretability, risk 117 for inherent bias due to the used data, difficulty to acquire physician adoption, explaining to 118 physicians why a new risk model might be superior to existing ones, with all of these hindering 119 widespread adoption of ML based risk prediction models (35,36). One example for ML based 120 CVD risk prediction is the AutoPrognosis based approach, where an ensemble of multiple ML 121 pipelines has also been applied on the UK Biobank dataset for 5-year CVD risk prediction (28). 122 Further, using a purely ML driven approach can lead to a model that requires too many risk. 123 factors to compute risk, which is infeasible for routine clinical check-ups. Another disadvantage 124 of purely data-driven approaches is the inclusion of risk factors which might show strong

125 correlations but are unrelated to the pathophysiology of CVDs or are not actionable, making
126 them inapplicable in a clinical setting or as an actionable self-management tool (28).

127

128 The aim of this study was to use a large-data ML approach to develop an actionable absolute 129 risk prediction tool which takes into account the holistic health of an individual and has a focus 130 on behavioral risk factors relating to atherosclerotic CVD outcomes. Our goal was to have a 131 highly holistic understanding of an individual's current health status, to better quantify their risk 132 of atherosclerotic CVDs and to provide actionable advice. We aimed to do this by taking multiple 133 biological layers into account, which are: (i) multi-omics data from blood samples (e.g. lipidome 134 and proteome); (ii) family history (e.g. genome), (iii) lifestyle data, (iv) clinical data and (v) 135 environmental data; along with (vi) an extensive set of risk factors and outcomes.

136

137 We used data from 464,547 participants of the UK Biobank study who did not have

138 atherosclerotic CVD at baseline. We created an automated pipeline to benchmark risk

139 prediction classifier algorithms against each other, then evaluated their predictive performances

140 in the overall population and tested the generalizability of the top-performing classifiers through

141 retraining and testing on different sub-populations. We explored the clinical implications of the

142 proposed classifiers, with a focus on the top-performing models. This study does not focus on

143 the algorithmic aspects of the utilized classifiers.

Methodological details on the utilized classifiers can be found in the open-source documentation
of the respective algorithms of the scikit-learn (37) and xgboost (38) libraries and in the
supporting information (S4 Table).

147

148 Materials and Methods

149 Study design and participants

150 The UK Biobank is a long-term prospective large-scale biomedical database including over 151 500,000 participants aged 40-69 years (when recruited between 2006 and 2010). The database 152 is globally accessible to approved researchers undertaking research into the most common and 153 life-threatening diseases and continuously collects phenotypic and genotypic data about its 154 participants, including data from questionnaires, physical measures, blood, urine and saliva 155 samples, lifestyle data (39). This data is further linked to each participant's health-related 156 records, accelerometry, multimodal imaging, genome-wide genotyping and longitudinal follow-157 up data for a wide range of health-related outcomes (39,40). The UK Biobank study protocol is 158 available online (41). 159 The North West Multi-centre Research Ethics Committee approved the UK Biobank study and 160 all participants provided written informed consent prior to study enrollment. Our research is 161 covered by the UK Biobank's Generic Research Tissue Bank (RTB) Approval and was 162 approved by the UK Biobank Access Management Team (42). 163 164 We excluded participants with atherosclerotic CVDs present before or during baseline, 165 participants who chose to leave the UKB study and participants who were lost due to various

166 reasons. The resulting cohort consisted of 464,547 participants. The last available date of

167 participant follow-up was March 5th, 2020.

168

169 **Risk factor definition**

We curated a list of all generally known risk factors and outcomes for atheroscelortic CVDs from the medical literature and from validated risk prediction models. This preliminary list of risk factors was reduced through curation to focus on those factors that were clearly involved in the pathophysiology of atherosclerosis and those that are modifiable through behavioral change. The curation was carried out by three medical doctors with experience in diagnosing or scientifically modelling cardiovascular diseases. We consolidated all relevant UKB columns into

176 203 risk factors and grouped them into six categories: demographics (e.g. age, biological sex, 177 ethnicity), biomarkers (e.g. cholesterol, glucose, blood pressure, heart rate), lifestyle (e.g. 178 alcohol consumption, smoking, physical activity, sleep, social visits), environment (e.g. exposure 179 to tobacco smoke, work and housing and other socio-economic related factors), genetics (e.g. 180 family history of cvd, stroke, diabetes, high cholesterol, high blood pressure) and comorbidities 181 (e.g. heart arrhythmias, diabetes, acute & chronic kidney injury, migraines, rheumatoid arthritis, 182 systemic lupus erythematosus, severe mental illnesses (schizophrenia, bipolar disorder, 183 depression, psychosis), diagnosis or treatment of erectile dysfunction, atypical antipsychotic 184 medication). A categorized list of all risk factors used in our analysis is provided in the 185 supplementary data (S1 Table).

186

187 Outcome definition

188 In the same manner as described above, an initial list of atherosclerotic CVDs was further 189 reviewed and curated by the same team of medical doctors. All resulting CVDs of interest are 190 associated with atherosclerotic plaque build-up, are modifiable and relate to the collected risk 191 factors only. Thus, we disregard brain haemorrhages due to accidents and congenital and 192 pregnancy-related CVDs, which are not actionable. The curated list of all ICD-10 and ICD-9 193 outcomes meeting the above criteria consists of 193 total (125 unique) CVD outcomes, e.g. 194 coronary/ischaemic heart disease, heart attack, angina, stroke, cardiac arrest, congestive heart 195 failure, left ventricular failure, myocardial infarction, aortic valve stenosis, cerebral artery 196 occlusions, nontraumatic haemorrhages. A list with all outcome codes used in our analysis is 197 provided in the supplementary data (S2 Table). An atherosclerotic CVD event was defined as 198 the first occurrence out of the following: any of the atherosclerotic CVD outcome diagnosis 199 codes, also as primary or secondary death cause during the 10-year follow-up period.

200

201 Cohort Follow-up

Follow-up time was set to 10 years as commonly used in other risk models (see table 2 in (7)) and counted from the date of one's initial assessment center visit. Individuals who died from other causes during their follow-up period or had a relevant CVD event past their individual follow-up period, were marked as not having had a relevant CVD event.

206

208

207 Models used in comparison

209 data of the two prospective studies, the Framingham Heart Study and the Framingham offspring

Framingham Risk Score. The Framingham 10-year CVD absolute risk score is based on the

study (26). The cohort consists of 8491 participants, with 4522 women and 3969 men who

attended a baseline examination between 30 and 74 years of age and were free of CVD. A

212 positive CVD outcome was defined as any of the following: coronary death, myocardial

213 infarction, coronary insufficiency, angina, ischemic stroke, hemorrhagic stroke, transient

214 ischemic attack, peripheral artery disease and heart failure.

215 Participants were followed-up for 12 years where 1174 participants developed a CVD. Two

216 biological sex-specific risk models were derived, where Body Mass Index (BMI) substitues lipid

217 measurements. The variables used were biological sex, age, total cholesterol, HDL cholesterol,

218 treated and untreated systolic blood pressure, smoking status and diabetes status.

The Framingham risk calculators and model coefficients are publicly available (43). We imputedmissing data using simple mean imputation.

221

QRisk3. The QRisk3 10-year CVD absolute risk score is based on a prospective open cohort
study using data from general practices (GPs), mortality and hospital records in England (27).
The cohort consists of 10.56 million patients between the age of 25 and 84 years, where 75% of
the patients were used for training and 25% for validation. Patients with a pre-existing CVD,

226 missing Townsend score or using statins were removed from the baseline. Patients were classified as having a positive CVD outcome when any of the following outcomes was present 227 228 during follow-up in the GP, hospital or mortality records: coronary heart disease, ischaemic 229 stroke, or transient ischaemic attack. QRisk3 used the following ICD-10 codes: G45 (transient 230 ischaemic attack and related syndromes), I20 (angina pectoris), I21 (acute myocardial 231 infarction), I22 (subsequent myocardial infarction), I23 (complications after myocardial 232 infarction), I24 (other acute ischaemic heart disease), I25 (chronic ischaemic heart disease), I63 233 (cerebral infarction), and I64 (stroke not specified as haemorrhage or infarction). The utilized 234 ICD-9 codes were: 410, 411, 412, 413, 414, 434, and 436. Participants were followed-up for 15 235 years where 363,565 participants of the training set (4,6%) developed a relevant CVD. One 236 biological sex-specific risk model was derived.

237 The risk factors used in the final model were age, ethnicity, deprivation, systolic blood pressure,

BMI, total cholesterol/HDL cholesterol ratio, smoking status, family history of coronary heart

disease, diabetes status, treated hypertension, rheumatoid arthritis, atrial fibrillation, chronic

240 kidney disease, systolic blood pressure variability, diagnosis of migraine, corticosteroid use,

241 systemic lupus erythematosus, atypical antipsychotic use, diagnosis of severe mental illnesses,

242 diagnosis or treatment of erectile dysfunction.

243 The QRisk3 risk calculator and model coefficients are publicly available (44), built into all major

244 NHS GP systems and included in the national guidelines

245 (https://www.healthcheck.nhs.uk/seecmsfile/?id=1687, accessed 10th November 2021). We

imputed missing data using simple mean imputation.

247

248 Standard linear and ML models. We compared regularized linear regression (with L1 penalty),

random forests and gradient boosting (xgboost implementation) for assessing the highest

- achievable Area Under the Receiver Operating Characteristic Curve (AUROC) value, which we
- 251 used for assessing the trade-off between number of features and predictive performance of

252 several simpler practical risk predictors, as determined by an iterative feature elimination 253 procedure outlined below. L1 regularization for logistic regression implements a strong penalty 254 for non-zero feature weights, resulting in a feature selection procedure that discards features 255 that are likely to be non-predictive. Random Forest is an ensemble method that fits many 256 decision trees independently to a subset of the data. We implemented both methods using their 257 scikit-learn library implementation. Finally, we evaluated Extreme Gradient Boosting: Gradient 258 boosting is an ensemble tree-based machine learning method that combines many weak 259 classifiers to produce a stronger one. It sequentially fits a series of classification or regression 260 trees, with each tree created to predict the outcomes misclassified by the previous tree (45). By 261 sequentially predicting residuals of previous trees, the gradient boosting process has a focus on 262 predicting more difficult cases and correcting its own shortcomings. Extreme Gradient Boosting 263 (XGB / XGBoost) is a specific implementation of the gradient boosting process, and uses 264 memory-efficient algorithms to improve computational speed and model performance (38,46). 265 For completeness, we evaluated a number of other standard classifiers, but discarded them due 266 to too high computational complexity or inferior performance so we do not report their 267 performances here: Decision Trees, Voting Classifiers, Multi-Layer Perceptrons with 2 layers 268 and 200 and 150 neurons each (Neural Network), stochastic gradient descent implementing a 269 support vector machine algorithm (47,48), Ada Boost (49,50), Gradient Boosting (45), K 270 Neighbors (51), Quadratic Discriminant Analysis (52) and Gaussian Naive Bayes (37,53). 271

272 Model development and benchmarking using pipeline

We built a benchmarking pipeline for automated and reproducible data extraction, normalization,
imputation, model training, tuning of model hyperparameters, classification, documentation and
reporting.

276 We implemented all models using their respective scikit-learn library or xgboost library 277 implementation using the Python programming language (37,38). Details on the used Python 278 libraries and methods are provided in the supplementary data (S3 and S4 Tables). 279 Categorical values were one-hot encoded. Data normalization was performed by removing the 280 mean and scaling to unit variance. Data imputation was performed for all models using a simple 281 mean imputation. The models' hyper-parameters were determined using grid search and 282 stratified k-fold cross validation using 3 folds to avoid overfitting. 283 Finally, we assessed model performance mainly using the AUROC.

284

285 **Iterative feature elimination**

We employed an iterative feature elimination procedure based on the regularized logistic regression for finding the best trade-off between predictive performance and number of risk factors, with the aim of creating a risk prediction algorithm that is applicable in the clinical context. We used the standard L1 regularization (also known as Lasso) proposed by (54); it implements a strong penalty on non-zero feature weights of our logistic regression model,

resulting in a sparse feature set for prediction.

A logistic regression coefficient value \Box can be interpreted as the expected change in log odds of having the outcome per unit change in the feature x_. Therefore, increasing the feature by one unit multiplies the odds of having the outcome by e^{β} . This means that we can interpret the coefficients as feature importance values in the sense that the feature with the smallest coefficient has the least importance on model predictions. Importantly, this holds only true in the context of the parameters contained in the current model. Thus, we re-estimate the model after each feature elimination round.

299 In each iteration, we re-estimated the logistic regression model on the remaining parameters,

and then discarded all parameters that were set to zero by the L1 regularization; finally, we also

- 301 discarded the parameter with the lowest non-zero absolute value.
- 302 As an additional step, we created a ranking of the relative feature importance value of each
- 303 feature by dividing its absolute coefficient weight by the sum of all absolute coefficient weights.
- 304

305 Statistical analysis

To reduce overfitting, we evaluated the classification performance of all our benchmarked algorithms by using 3-fold stratified cross-validation and measuring the Area Under the Receiver Operating Characteristic Curve. For the cross-validation, we used a training set with 325,182 participants to train and derive our standard linear and ML models and then assessed the AUROC performance on the held-out test set with 139,365 participants using 203 risk factors respectively. We report the AUROC and the 95% confidence intervals (Wilson score intervals) for all models.

313

314 Generalizability

With 442,620 out of the 502,551 patients in the UK Biobank, the cohort has a high proportion (88.1%) of participants with British ethnicity. In an effort to estimate a proxy for out-of-sample generalizability, we re-trained the two best models, XGB and Logistic Regression with L1 regularization, only on whites and tested their performance on a non-white test set. The whiteonly training set consists of 378,836 participants (81.5%). The non-white test set consists of 85,711 participants (18.5%).

321

322 **Results**

323 Characteristics of the training and test populations

Of 502,551 patients in the UK Biobank, we filtered out 7.6% who already experienced a relevant

325 CVD outcome (during or before baseline) and the participants being lost or who withdrew from

the biobank. This resulted in 464,547 participants who met the inclusion criteria. 28,561 (6.1%)
of those participants developed at least one of the relevant CVD outcomes during their 10-year
follow-up period. We used a common 70% of the data as a training set and 30% as a hold-out
test set. Table 1 shows the overlap of our atherosclerotic CVD outcome definition with the CVD
outcome definition used in the related work approach by Alaa et al. (28):

331

332Table 1. CVD outcomes statistics according to definition in current study and the

333 comparator study definition by Alaa et al. (28).

Statistic measured	Number
No. of atherosclerotic CVD outcomes that developed in 10-year follow-up according to definition in current study	28,561
No. of CVD outcomes that developed in 10- year follow-up according to comparator study definition	28,242
No. of CVD outcomes after 10-year follow-up that overlap in the current study and comparator study definition	456,184 out of 464,547 (98%)
No. of CVD outcomes identified in the current study but not in comparator studies	4,341
No. of CVD outcomes included in comporator studies, but not in current study	4,022

334

335 **Prediction accuracy**

336 **Comparison of prediction models.** The resulting prediction accuracy of the benchmarked

models is depicted in Table 2. We used both Framingham 10-year CVD risk versions, with and

338 without lipids, as well as QRisk3 as baseline models to assess the performance of predicting

- 339 someone's 10-year risk of developing an atherosclerotic cardiovascular disease based on a
- 340 holistic set of risk factors, with a focus on actionable risk factors and outcomes. The best
- performing model was XGB with an AUROC of 75.73%, only marginally higher than the Logistic
- Regression model with L1 regularization (75.44%) and substantially better than the Random
- 343 Forest model (66.90%).

344	Table 2.	Performance of	all	tested	classifiers	including	baseline	models.

No.	Algorithm Name	AUROC and 95% confidence intervals
1	Extreme Gradient Boosting	0.7573
	Logistic Regression with L1	0.7544
2	regularization	(0.755-0.7595)
3	QRisk3	0.725 (0.7226-0.7273)
4	Framingham Lipid & BMI	0.680 (0.6775-0.6824) & 0.681 (0.6788-0.6837)
5	Random Forest	0.6690 (0.6666-0.6715)

345

Fig 1 shows the AUROCs of the best performing models XGB and from Logistic Regression
with L1 regularization, which is the simplest model tested and amongst the top two best
performing models. Logistic Regression comes with the advantages of being interpretable by

providing reasoning for its classifications, and being a simple and robust method (35).

350 In order to better evaluate the clinical implications and significance of our results, we compared

the results of our benchmarked models with our baseline models Framingham and QRisk3.

352 Table 2 shows that both, our XGB and Logistic Regression classifiers achieved superior

353	performance compared to the baseline models. Apart from the Random Forest model, all tested
354	models had a higher AUROC than both baseline Framingham (68.0% and 68.1%) and QRisk3
355	(72.5%) models.

356 The difference in AUROC performance of the Framingham score in our experiments in Fig 1 357 and the one stated from Alaa et al. (28) in their study are explainable by the related work 358 approach using an older UK Biobank version with 40,000 fewer baseline patients and their last 359 available date of participant follow-up being February 17, 2016. Furthermore, our UK Biobank 360 version has biochemistry data which was released May 1, 2019 including cholesterol and 361 additional questionnaires data which the related approach did not have. Additionally, more 362 diagnosis data was made available over time. These dataset differences explain the difference 363 in AUROC. 364 365 Fig 1. AUROC of Logistic Regression with L1 regularization and XGBoost 366 367 Figs 2 and 3 show the AUROCs of all baseline models on imputed and unimputed data 368 respectively. 369 370 Fig 2. AUROC curves of baseline models on imputed data

- 371
- 372

373 Fig 3. AUROC curves of baseline models on unimputed data

374

375 Both Framingham versions perform nearly identically on imputed and unimputed data whereas

- 376 QRisk3 performs worse on unimputed data.
- 377 Feature elimination vs. predictive performance

Fig 4 shows how the performance of the best Logistic Regression model depends on the number of risk factors used. Stepwise discarding the risk factors leads to a relatively unchanged and stable model performance until around 170 iterations of feature elimination. This indicates that for predicting an individual's 10-year atherosclerotic CVD risk, many features provide only marginal value and a small subset of features provides substantial informative value. After around 170 iterations, there was a marked decline in model performance associated with further reductions in utilized features.

385

386

387 Fig 4. Performance of best Logistic Regression model depending on number of features.

AUROC performance of best performing Logistic Regression model with L1 regularization
(continuous blue line) compared to number of features utilized in each iterative feature
elimination step (orange line), dotted blue horizontal line showing intersection of 25 features
with iterative feature elimination step, allowing for extrapolation to model performance.

Table 3 shows in more detail the dependence of the model performance on the number of
features. Utilizing only 25 (88%) out of the 203 total risk factors still leads to a reasonable
AUROC performance, with a high reduction in utilized features. Compared to the model
performance with an AUROC of 75.44% when using all 203 risk factors, the model still achieves
74.15% with the 25 most informative risk factors.

We also assessed the concrete performance for fewer features. To reach the same

performance as QRisk3 of 72.5% AUROC, 16 features would be necessary. The two most

400 informative features are age and biological sex. To reach a similar performance as Framingham

401 (68.0%), two features would be necessary (68.98%). It is worth noting that both Framingham

402 and QRisk3 were trained and tuned on other datasets and have different CVD definitions and

403 objectives.

404

- 405 Table 3. Performance of best Logistic Regression model depending on number of
- 406 features.

Number of Features	AUROC
203	75.44
40	75.01
25	74.15
20	73.32
17	72.76
10	70.88
2	68.98

407

408 Generalizability results

409 We assessed the generalizability of our models with the aforementioned approach of re-training

410 the two previously best performing models only on a white cohort and testing them on a non-

411 white cohort. Table 4 and Fig 5 show the results for Logistic Regression and XGB. The Logistic

412 Regression model has an AUROC of 75.86% in the generalizability experiment, compared with

- 413 an AUROC of 75.44% in the previous experiment. XGB has an AUROC of 76.26% in the
- 414 generalizability experiment and 75.73% in the previous experiment. These results show

415 marginal differences to the results of the previous experiments.

417 Table 4. Model performance when trained on whites and tested on non-whites.

Model	AUROC on generalizability experiment	Previous AUROC results
Logistic Regression with L1 regularization	75.86%	75.44%
XGBoost	76.26%	75.73%

418

419

420 Fig 5. AUROC of Logistic Regression with L1 regularization and XGBoost when trained

421 on whites and tested on non-whites.

422 **Predictive ability of individual variables in UK Biobank.**

423 Table 5 shows the relative regression feature weights of the 25 most informative risk factors in

424 descending order. A full list is provided in the supplementary materials (S5 Table). Based on our

425 previous manual curation of risk factors and outcomes, we can see that the most informative

426 risk factors are distributed across 5 categories (Table 6). The two most informative features

427 were age and biological sex.

428

429 Table 5. Relative regression feature weights of 25 most informative risk factors from best

430 Logistic Regression model.

		Relative
Feature		informative value
number	Risk factor name	descending

1	Age	0.0938
2	Biological sex	0.0485
3	Systolic blood pressure	0.0284
4	Social visits: About once a week	0.0277
5	Social visits: 2-4 times a week	0.0273
6	Walking pace: Brisk pace	0.0268
7	Total cholesterol HDL ratio	0.0267
8	Total cholesterol	0.0239
9	LDL cholesterol	0.0235
10	Familial CVD	0.0218
	Social visits: About once a	
11	month	0.0203
12	Sleep problems: Not at all	0.0188
13	Alcohol with meals: Yes	0.0184
14	Smoking	0.0184
15	Social visits: Almost daily	0.0178
16	No. of cigarettes daily	0.0163
17	Hypertension	0.0160
18	Walking pace: Steady average	0.0154

	pace	
19	Waist circumference	0.0150
20	Alcohol with meals: It varies	0.0141
	Social visits: Once every few	
21	months	0.0139
22	Overall health rating: Excellent	0.0134
23	Other Heart Arrhythmias	0.0129
24	Overall health rating: Poor	0.0123
25	Sleep problems: Several days	0.0122

431

432 Table 6. Categorization of the 25 most informative risk factors into categories from the

433 best Logistic Regression model.

Category	Risk Factors
Demographics	Age, Biological sex
Biomarkers	Waist circumference, systolic blood pressure, total cholesterol, LDL cholesterol, total cholesterol HDL ratio
Comorbidities	Hypertension, sleep problems: not at all, sleep problems: several days, other heart arrhythmias
Family History	Familial CVD

Lifestyle Factors	Social visits: about once/week, social visits:
	2-4 times/week, social visits: about
	once/month, social visits: almost daily, social
	visits: once every few months, smoking, no.
	of cigarettes daily, alcohol with meals: yes,
	alcohol with meals: it varies, walking pace:
	steady average pace, walking pace: Brisk
	pace, overall health rating: excellent, overall
	health rating: poor

434

435 **Discussion**

436 Using data gathered from the large longitudinal cohort UK Biobank study, we developed a 437 pipeline to benchmark several classification models for predicting a subject's 10-year absolute 438 risk of developing an atherosclerotic CVD. We used an extensive set of physician curated risk 439 factors and outcomes methodology, employing a holistic view of the subject's current health 440 status rooted in a precision medicine approach. The models were trained and evaluated using 441 data from 464,547 UK Biobank participants, spanning 203 CVD risk factors for each subject. 442 Using a simple Logistic Regression model with a holistic set of risk factors significantly improved 443 the accuracy of atherosclerotic CVD risk prediction compared to currently available, widely used 444 and recommended models such as Framingham and QRisk3. Both of these existing models rely 445 on a limited set of risk factors and outcomes and do not focus on modifiable lifestyle factors. 446 Further, our best performing Logistic Regression model utilizes new CVD risk predictors 447 showing high predictive power, which are social visits, walking pace and overall health rating. 448 The frequency of social visits could be indicative of someone's current mental health status, 449 which has been shown to be a relevant CVD risk factor (55,56). These and other non-laboratory 450 risk factors could be collected by means of a questionnaire or passively deduced using data 451 analytics from data sources such as GPS, calendar and sensors from smartphones,

452 smartwatches and fitness trackers.

Additionally, our best performing models, XGBoost and Logistic Regression, showed marginal
 differences when trained and tested on particular sub-populations, which is indicative of good
 generalizability to other ethnicities.

As there was little performance difference between the best performing models, we primarily discuss the simplest model, Logistic Regression with L1 regularization. This model has the inherent benefit of offering reasoning for its predictions, through analyzing the learned coefficients for every risk factor and having feature selection performed by the L1 regularization. With L1 regularization, less important risk factors' coefficients are minimised and also set to zero, which then leads to entire removal of these features from the model, and fewer risk factors needed for an accurate prediction.

463

464 Using iterative feature elimination, we identified a subset of the 25 most relevant risk factors 465 providing a similar performance compared to using all 203 risk factors. With the 25 most 466 relevant risk factors belonging to five different categories, suggests that different biological 467 layers contribute to the risk of atherosclerotic CVD. This result indicates that it is insufficient to 468 assess only one biological layer for accurate risk prediction, confirming the findings of other 469 studies for identifying novel biomarkers and pathways in complex diseases (57). This result 470 supports our initial model development approach: to use a holistic model for an individual's 471 health. Our approach was rooted in precision medicine and takes into account multiple 472 biological layers by using multi-omics as well as clinical and lifestyle data with the aim to capture 473 all potential interactions or correlations detected between molecules in different biological layers 474 (22). Multi-omics data generated for the same set of samples can provide useful insights into 475 the interaction of biological information at multiple layers and thus can help in understanding the 476 mechanisms underlying the complex biological condition of interest.

477

478 In our model, the lifestyle category contributed the most risk factors, suggesting that it is 479 essential to include someone's daily lifestyle data and not just periodic snapshots of clinical data 480 into an individual's risk assessment for a complex disease like CVD. The causal relationships 481 between the risk factors considered in our model and atherosclerotic CVDs have been 482 demonstrated by other studies (11,19,21,25). Innovative approaches are needed in order to 483 tackle the increasing prevalence and mortality of CVD-related diseases (2), and the associated 484 healthcare systems' financial burdens. This is especially required in low and middle income 485 countries where CVD prevalence has also been increasing and is expected to increase as a 486 consequence of an aging and growing population (2).

487

488 There is potential for novel disruptive approaches to affordably improve CVD outcomes. Areas 489 where this may have an impact is in novel approaches to screening, lifestyle coaching and 490 prevention (2). Screening will become more accessible and widespread by more (near-)medical-491 grade sensors being integrated into smartphones and smartwatches, enabling continuous 492 monitoring of relevant behavioral CVD risk factors, as well as biomarkers such as heart rate, 493 blood pressure and blood glucose. By gathering a wider spectrum of relevant risk factors for 494 cardiovascular disease automatically and continuously, an ongoing and personalized 495 cardiovascular disease risk prediction could be enabled. Through linking personalised 496 information on an individual's CVD risk with app-based programmes for sustained behavioural 497 modification, it may be possible to lower the incidence and mortality of CVDs (58). Combined 498 with a companion smartphone-based app, an AI or healthcare provider-generated personalised 499 intervention program could be provided, and targeted at those people who need it the most. 500 Many studies have shown that digital health interventions are cost effective for managing CVD 501 (for a review see (59)). One report found that a community-based prevention program could 502 have a mean return on investment (ROI) on medical cost savings of \$5.60 for every \$1 spent 503 within a 5 year timeframe by improving physical activity and nutrition and reducing tobacco

usage (60). A review of 11 in-home cardiac rehabilitation programs for the secondary prevention
of CVD found that social support, goal setting, monitoring, credible instructions and literature
resources are all effective behavior change techniques to reduce behavioral risk factors for CVD
(61).

508

509 The improvement achieved by our models might be partially attributed to being trained and 510 assessed on the UK Biobank dataset, whereas the baseline Framingham model was derived 511 from a different population. The population and many of the data sources used in the QRisk3 512 model are similar, being the general UK population and using their GP, hospital and mortality 513 records. However, our risk model generation approach and QRisk3's approach were designed 514 with different aims and objectives and the modelling strategy was different. For these reasons, 515 direct comparison between the models is limited. Notable differences between the approaches 516 include a more limited set of risk factors included in Framingham and QRisk3's and a focused 517 and wider range of atherosclerotic CVDs included in our approach.

518

The results from our generalizability subanalysis indicate that our XGB and Logistic Regression models might generalize well to other ethnicities and do not overfit to our cohort, however, this needs to be further evaluated with more data from diverse ethnicities.

522

523 Our results show that our models have improved performance over the baseline models 524 Framingham and QRisk3 (Table 2). This is because the selection of the appropriate disease 525 modelling approach, classifiers and careful tuning of the model's hyperparameters are crucial 526 steps for realizing the potential benefits of ML. Our pipeline automates some of these steps 527 which makes the tuning and discovery of new disease risk models easily accessible for clinical 528 research. Our prospective cohort modelling approach, which is rooted in precision medicine, is

the first to generate an atherosclerotic CVD absolute risk prediction tool based upon a completedefinition of atherosclerotic CVD outcomes and a holistic set of risk factors.

531

532 Limitations

533 The UK Biobank only admitted participants for their initial signup from the ages 40 and up. This 534 might limit the applicability of the risk score for younger populations and further tests with data 535 from younger populations need to be conducted.

536

537 There are many missing data values related to the potential risk factors for many participants.

538 Having more unimputed data of relevant CVD risk factors could improve the predictive

539 performance of all our benchmarked classifiers and could also lead to changes in the classifier

ranking from Table 2 and relative risk factor importances in Table 5. However, the use of

541 imputed data is highly unlikely to have an impact on our conclusion that a holistic set of risk

542 factors and an exhaustive atherosclerotic CVD outcome definition could improve atherosclerotic

- 543 and actionable CVD risk prediction.
- 544

An additional limitation of our study is that the UK Biobank dataset consists of participants of predominantly (88%) British ethnicity, with an even larger portion having a white background (91%). Therefore, further assessments of the influence of the ethnicity predictor need to be carried out to enable a generalizable tool. Previous work in this area indicates that the plaque growth process seems to be independent of ethnicity (21).

550 A further limitation of this UK focused dataset is that socio-economic and other environmental 551 factors differ between countries. This is another potential bias that needs to be further evaluated 552 with datasets from other countries with different socio-economic characteristics.

553

554 Disease risk prediction models which include subjective non-laboratory risk factors, such as the 555 self-reported health rating and usual walking pace, should be cautiously evaluated to minimize 556 self-reported bias. These risk factors have been found to be good predictors of someone's 557 overall CVD risk in another study using UK Biobank data (28).

558

559 **Conclusions**

560 We benchmarked multiple classifiers to predict an individual's 10-year risk of developing an 561 atherosclerotic CVD, using a holistic set of risk factors and a specific definition of atherosclerotic 562 CVDs. Our reduced Logistic Regression with L1 regularization classifier, a simple and interpretable model, is amongst our best prediction models, includes actionable lifestyle factors, 563 564 has great predictive power and requires 13 unique features. Our experiments showed that a two 565 feature-questionnaire is as accurate as the Framingham models and a 16 feature-questionnaire 566 is as accurate as QRisk3 for 10-year atherosclerotic CVD risk prediction. Both prediction 567 models, XGBoost and Logistic Regression, generalize well to non-white people, which might 568 indicate that our models generalize well to other (western) countries. Framingham and QRisk3, 569 which are well established and validated absolute risk prediction models, do not perform as well on predicting individuals' 10-year risk of developing an atherosclerotic CVD. With our Logistic 570 571 Regression model, we created a promising new interpretable, actionable and accurate risk 572 prediction tool that could assist individuals and public health in CVD risk reduction.

573

574 Acknowledgments

575

576 Author Contributions

577 **Conceptualization.** Ajay Kesar, Stephen Gilbert, Paul Wicks, Bernard Leon Stopak

- 578 Data Curation. Ajay Kesar, Adel Baluch, Omer Barber, Milan Jovanovic
- 579 Formal Analysis. Ajay Kesar, Daniel Renz
- 580 **Funding Acquisition.** Stephen Gilbert, Bernard Leon Stopak, Henry Hoffmann
- 581 **Investigation.** Ajay Kesar
- 582 Methodology. Ajay Kesar, Daniel Renz
- 583 **Project Administration.** Ajay Kesar
- 584 **Resources.** Ajay Kesar, Stephen Gilbert, Bernard Leon Stopak, Henry Hoffmann
- 585 **Software.** Ajay Kesar, Daniel Renz
- 586 Supervision. Stephen Gilbert, Henry Hoffmann
- 587 Validation. Ajay Kesar, Daniel Renz
- 588 Visualization. Ajay Kesar
- 589 Writing Original Draft Preparation. Ajay Kesar, Daniel Renz, Paul Wicks, Stephen Gilbert
- 590 Writing Review & Editing. Ajay Kesar, Henry Hoffmann, Daniel Renz, Bernard Leon Stopak,
- 591 Paul Wicks, Stephen Gilbert
- 592

593

594 **References**

- Cardiovascular diseases (CVDs) [Internet]. [cited 2021 Sep 28]. Available from: https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds)
- Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM, et al. Global
 Burden of Cardiovascular Diseases and Risk Factors, 1990–2019. J Am Coll Cardiol. 2020
 Dec 22;76(25):2982–3021.
- Heidenreich PA, Trogdon JG, Khavjou OA, Butler J, Dracup K, Ezekowitz MD, et al.
 Forecasting the Future of Cardiovascular Disease in the United States. Circulation. 2011
 Mar 1;123(8):933–44.

- Weintraub WS, Daniels SR, Burke LE, Franklin BA, Goff DC, Hayman LL, et al. Value of
 Primordial and Primary Prevention for Cardiovascular Disease. Circulation. 2011 Aug
 23;124(8):967–90.
- 5. Evsikova C, Raplee I, Lockhart J, Jaimes G, Evsikov A. The Transcriptomic Toolbox:
 Resources for Interpreting Large Gene Expression Data within a Precision Medicine
 Context for Metabolic Disease Atherosclerosis. J Pers Med. 2019 Apr 29;9:21.
- 609 6. Nichols GA, Bell TJ, Pedula KL, O'Keeffe-Rosetti M. Medical care costs among patients 610 with established cardiovascular disease. Am J Manag Care. 2010 Mar 1;16(3):e86–93.
- 7. Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular
 Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016 Aug 1;37(29):2315–81.
- 8. 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk. J Am Coll Cardiol.
 2014 Jul 1;63(25 0 0):2935–59.
- Sedgwick JEC. Absolute, attributable, and relative risk in the management of coronary
 heart disease. Heart. 2001 May 1;85(5):491–2.
- Jackson R. Guidelines on preventing cardiovascular disease in clinical practice: Absolute
 risk rules—but raises the question of population screening. BMJ. 2000 Mar
 11;320(7236):659–61.
- Libby P, Bonow RO, Mann DL, Tomaselli GF, Zipes DP. Braunwald's Heart Disease E Book: A Textbook of Cardiovascular Medicine. Elsevier Health Sciences; 2018. 2527 p.
- Eriksen CU, Rotar O, Toft U, Jørgensen T. What is the effectiveness of systematic
 population-level screening programmes for reducing the burden of cardiovascular
 diseases? [Internet]. Copenhagen: WHO Regional Office for Europe; 2021 [cited 2021 Oct
 12]. (WHO Health Evidence Network Synthesis Reports). Available from:
 http://www.ncbi.nlm.nih.gov/books/NBK567843/
- Lim LS, Haq N, Mahmood S, Hoeksema L. Atherosclerotic Cardiovascular Disease
 Screening in Adults: American College of Preventive Medicine Position Statement on
 Preventive Practice. Am J Prev Med. 2011 Mar 1;40(3):381.e1-381.e10.
- Espinoza J, Crown K, Kulkarni O. A Guide to Chatbots for COVID-19 Screening at
 Pediatric Health Care Facilities. JMIR Public Health Surveill. 2020 Apr 30;6(2):e18808.
- 637 15. Perez MV, Mahaffey KW, Hedlin H, Rumsfeld JS, Garcia A, Ferris T, et al. Large-Scale
 638 Assessment of a Smartwatch to Identify Atrial Fibrillation. N Engl J Med. 2019 Nov
 639 14;381(20):1909–17.

- Lemmen C, Simic D, Stock S. A Vision of Future Healthcare: Potential Opportunities and
 Risks of Systems Medicine from a Citizen and Patient Perspective—Results of a
 Qualitative Study. Int J Environ Res Public Health. 2021 Sep 19;18(18):9879.
- Peeters JM, Krijgsman JW, Brabers AE, Jong JDD, Friele RD. Use and Uptake of eHealth
 in General Practice: A Cross-Sectional Survey and Focus Group Study Among Health
 Care Users and General Practitioners. JMIR Med Inform. 2016 Apr 6;4(2):e4515.
- Bui QT, Prempeh M, Wilensky RL. Atherosclerotic plaque development. Int J Biochem Cell
 Biol. 2009 Nov 1;41(11):2109–13.
- Herrington W, Lacey B, Sherliker P, Armitage J, Lewington S. Epidemiology of
 Atherosclerosis and the Potential to Reduce the Global Burden of Atherothrombotic
 Disease. Circ Res. 2016 Feb 19;118(4):535–46.
- Bentzon JF, Otsuka F, Virmani R, Falk E. Mechanisms of Plaque Formation and Rupture.
 Circ Res. 2014 Jun 6;114(12):1852–66.
- Insull W. The Pathology of Atherosclerosis: Plaque Development and Plaque Responses
 to Medical Treatment. Am J Med. 2009 Jan 1;122(1, Supplement):S3–14.
- Picard M, Scott-Boyer M-P, Bodein A, Périn O, Droit A. Integration strategies of multiomics data for machine learning analysis. Comput Struct Biotechnol J. 2021 Jan
 1;19:3735–46.
- Collins FS, Varmus H. A New Initiative on Precision Medicine [Internet].
 https://doi.org/10.1056/NEJMp1500523. Massachusetts Medical Society; 2015 [cited 2021
 Sep 29]. Available from: https://www.nejm.org/doi/10.1056/NEJMp1500523
- Leon-Mimila P, Wang J, Huertas-Vazquez A. Relevance of Multi-Omics Studies in
 Cardiovascular Diseases. Front Cardiovasc Med. 2019;6:91.
- Fruchart J-C, Nierman MC, Stroes ESG, Kastelein JJP, Duriez P. New Risk Factors for
 Atherosclerosis and Patient Risk Assessment. Circulation. 2004 Jun
 15;109(23_suppl_1):III–15.
- b'Agostino RB, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, et al. General
 cardiovascular risk profile for use in primary care: the Framingham Heart Study.
 Circulation. 2008 Feb 12;117(6):743–53.
- Hippisley-Cox J, Coupland C, Brindle P. Development and validation of QRISK3 risk
 prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort
 study. BMJ. 2017 May 23;357:j2099.
- Alaa AM, Bolton T, Angelantonio ED, Rudd JHF, Schaar M van der. Cardiovascular
 disease risk prediction using automated machine learning: A prospective study of 423,604
 UK Biobank participants. PLOS ONE. 2019 May 15;14(5):e0213653.
- Conroy RM, Pyörälä K, Fitzgerald AP, Sans S, Menotti A, De Backer G, et al. Estimation of
 ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J.
 2003 Jun 1;24(11):987–1003.

- SCORE2 working group and ESC Cardiovascular risk collaboration. SCORE2 risk
 prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in
 Europe. Eur Heart J. 2021 Jul 1;42(25):2439–54.
- 31. Dolezalova N, Reed AB, Despotovic A, Obika BD, Morelli D, Aral M, et al. Development of
 an accessible 10-year Digital CArdioVAscular (DiCAVA) risk assessment: a UK Biobank
 study. Eur Heart J Digit Health. 2021 Sep 1;2(3):528–38.
- Kopitar L, Kocbek P, Cilar L, Sheikh A, Stiglic G. Early detection of type 2 diabetes mellitus
 using machine learning-based prediction models. Sci Rep. 2020 Jul 20;10(1):11981.
- 33. Ngiam KY, Khor IW. Big data and machine learning algorithms for health-care delivery.
 Lancet Oncol. 2019 May 1;20(5):e262–73.
- 688 34. Doupe P, Faghmous J, Basu S. Machine Learning for Health Services Researchers. Value
 689 Health. 2019 Jul 1;22(7):808–15.
- Adadi A, Berrada M. Explainable AI for Healthcare: From Black Box to Interpretable
 Models. In: Bhateja V, Satapathy SC, Satori H, editors. Embedded Systems and Artificial
 Intelligence. Singapore: Springer Singapore; 2020. p. 327–37.
- 693 36. He J, Baxter SL, Xu J, Xu J, Zhou X, Zhang K. The practical implementation of artificial
 694 intelligence technologies in medicine. Nat Med. 2019 Jan;25(1):30–6.
- 695 37. Pedregosa F, Varoquaux G, Gramfort A, Michel V, Thirion B, Grisel O, et al. Scikit-learn:
 696 Machine Learning in Python. J Mach Learn Res. 2011;12(85):2825–30.
- 697 38. Chen T, Guestrin C. XGBoost: A Scalable Tree Boosting System. Proc 22nd ACM
 698 SIGKDD Int Conf Knowl Discov Data Min. 2016 Aug 13;785–94.
- Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J, et al. UK Biobank: An Open Access Resource for Identifying the Causes of a Wide Range of Complex Diseases of Middle and Old Age. PLOS Med. 2015 Mar 31;12(3):e1001779.
- 40. About us [Internet]. [cited 2021 Nov 9]. Available from: https://www.ukbiobank.ac.uk/learn more-about-uk-biobank/about-us
- 41. Collins R. UK Biobank Protocol. :112.
- 42. Ethics [Internet]. [cited 2021 Nov 9]. Available from: https://www.ukbiobank.ac.uk/learn more-about-uk-biobank/about-us/ethics
- 43. Cardiovascular Disease (10-year risk) | Framingham Heart Study [Internet]. [cited 2021
 Nov 10]. Available from: https://framinghamheartstudy.org/fhs-riskfunctions/cardiovascular-disease-10-year-risk/
- 710 44. QRISK3 [Internet]. [cited 2021 Nov 10]. Available from: https://qrisk.org/three/index.php
- Friedman JH. Greedy Function Approximation: A Gradient Boosting Machine. Ann Stat.
 2001;29(5):1189–232.

- 46. XGBoost Documentation xgboost 1.6.0-dev documentation [Internet]. [cited 2021 Nov
 8]. Available from: https://xgboost.readthedocs.io/en/latest/
- 47. Hearst MA, Dumais ST, Osuna E, Platt J, Scholkopf B. Support vector machines. IEEE
 Intell Syst Their Appl. 1998 Jul;13(4):18–28.
- Zhang T. Solving large scale linear prediction problems using stochastic gradient descent algorithms. In: Proceedings of the twenty-first international conference on Machine learning [Internet]. New York, NY, USA: Association for Computing Machinery; 2004 [cited 2021 Nov 12]. p. 116. (ICML '04). Available from: https://doi.org/10.1145/1015330.1015332
- Freund Y, Schapire RE. A Decision-Theoretic Generalization of On-Line Learning and an
 Application to Boosting. J Comput Syst Sci. 1997 Aug 1;55(1):119–39.
- 50. Hastie T, Rosset S, Zhu J, Zou H. Multi-class AdaBoost. Stat Interface. 2009;2(3):349–60.
- 51. Omohundro SM. Five balltree construction algorithms. International Computer Science
 Institute Berkeley; 1989.
- 52. Srivastava S, Gupta MR, Frigyik BA. Bayesian quadratic discriminant analysis. J Mach
 Learn Res. 2007;8(6).
- 53. Zhang H. The optimality of naive Bayes. AA. 2004;1(2):3.
- Tibshirani R. Regression Shrinkage and Selection Via the Lasso. J R Stat Soc Ser B
 Methodol. 1996;58(1):267–88.
- 55. Correll CU, Solmi M, Veronese N, Bortolato B, Rosson S, Santonastaso P, et al.
 Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large-scale meta-analysis of 3,211,768 patients and 113,383,368 controls. World Psychiatry. 2017;16(2):163–80.
- 56. Cunningham R, Poppe K, Peterson D, Every-Palmer S, Soosay I, Jackson R. Prediction of
 cardiovascular disease risk among people with severe mental illness: A cohort study.
 PLOS ONE. 2019 Sep 18;14(9):e0221521.
- Fragman Strain Strain
- 58. Gao W, Yu C. Wearable and Implantable Devices for Healthcare. Adv Healthc Mater. 2021
 Sep 1;10(17):2101548.
- 59. Jiang X, Ming W-K, You JH. The Cost-Effectiveness of Digital Health Interventions on the
 Management of Cardiovascular Diseases: Systematic Review. J Med Internet Res. 2019
 Jun 17;21(6):e13166.
- 745 60. Trust for America's Health. Prevention for a healthier America: Investments in disease
 746 prevention yield significant savings, stronger communities. 2008;

- Heron N, Kee F, Donnelly M, Cardwell C, Tully MA, Cupples ME. Behaviour change
 techniques in home-based cardiac rehabilitation: a systematic review. Br J Gen Pract.
 2016 Oct;66(651):e747–57.
- 750

751 Supporting Information

- 752 S1 Table. List of all risk factors used in our analysis. (XLSX)
- 753 The listed risk factors were summarized into 203 risk factors for the respective UK Biobank
- 754 participant.
- 755 S2 Table. List of all outcomes used in our analysis. (XLSX)
- The following outcomes were all consolidated into one final binary outcome column indicating if
- 757 the respective UK Biobank participant did or did not develop one the relevant atherosclerotic
- 758 CVDs during their individual 10-year follow-up period starting from their individual initial
- 759 assessment attendance date.
- 760 S3 Table. Specifications of the python (v3.9.6) libraries and their versions used in this
- 761 **study.** (PDF)
- 762 S4 Table. List of utilized open-source methods, best parameters and references. (PDF)
- 763 S5 Table. Full list of relative informative values for each risk factor for best performing
- 764 Logistic Regression model. (XLSX)









